Liquidia Technologies is trading 4.79% lower now at $26.65 after a Delaware federal court ruled that Yutrepia infringes two valid United Therapeutics patent claims covering its PH-ILD use.
- Reuters said the September 30 ruling damaged Yutrepia’s commercial outlook.
- Liquidia plans to seek removal of the indication from the label and pursue appellate options; the ruling may limit Yutrepia’s U.S. market.
- Biotech is lower pre-market, but the patent setback outweighs sector weakness; no reliable volume figure was provided.